Thai buy expands Fuji's production base and hones DKSH's market expansion focus
This article was originally published in Scrip
Executive Summary
Japan's Fuji Pharma has agreed to pay around ¥4.2 billion ($53.6 million) to acquire the largest facility in Thailand for the contract manufacture of pharmaceuticals, in a deal that will also relieve current owner DKSH of a non-core asset.